Conventional imaging techniques such as MRI, CT, and bone scans have been used as standard in prostate cancer clinical trials for decades; however, in recent years, PET diagnostic methods, such as PSMA-PET and choline PET/CT, have demonstrated greater accuracy and sensitivity than conventional imaging allowing for earlier diagnosis of more advanced prostate cancer [21, 22]. The gene discussed is FOLH1; the disease is prostate carcinoma.